All Stories

Bristol Myers Squibb notches overall survival win with Opdivo in pre-operative NSCLC

Bristol Myers Squibb has bolstered its case for Opdivo to be used as a pre-operative treatment for non-small cell lung cancer (NSCLC) as it has delivered an overall survival (OS) edge when added to chemotherapy.

Feb 19, 2025 - 16:43
 0
Bristol Myers Squibb notches overall survival win with Opdivo in pre-operative NSCLC
Bristol Myers Squibb has bolstered its case for Opdivo to be used as a pre-operative treatment for non-small cell lung cancer (NSCLC) as it has delivered an overall survival (OS) edge when added to chemotherapy.
Read More

Tags:

Previous Article

Four Seasons, Nashville Collaborates with Lucid Motors for Complimentray EV Cars...

Next Article

Ascletis' swift surge into obesity continues with competitive oral GLP-1 data

Related Posts

With new FDA approval, GSK joins Pfizer in the 5-in-1 meningococcal vaccine ring

With new FDA approval, GSK joins Pfizer in the 5-in-1 m...

Feb 15, 2025  0

Challenging powerhouse Pfizer, BridgeBio's launch of Attruby is off to a 'great start,' analyst says

Challenging powerhouse Pfizer, BridgeBio's launch of At...

Feb 20, 2025  0

J&J takes Samsung Bioepis to court over claims Korean company breached Stelara biosim settlement

J&J takes Samsung Bioepis to court over claims Korean c...

Feb 25, 2025  0